New drug combo shows promise for chinese men with advanced prostate cancer

NCT ID NCT04076059

Ongoing Disease control Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it took for PSA levels to rise, a sign of cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enzalutamide (Xtandi)
What this could lead to: If successful, this combination could become a new standard treatment for Chinese men with metastatic hormone-sensitive prostate cancer, delaying disease progression.
What could go wrong: This is a phase 3 trial, but results may not apply to all populations. Side effects of enzalutamide include fatigue, hot flashes, and high blood pressure. The study is complete but not yet published.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

Contacts and locations

Locations

Site CN86001

Guangzhou, China
Site CN86002

Shanghai, China
Site CN86003

Shanghai, China
Site CN86004

Nanchang, China
Site CN86005

Ürümqi, China
Site CN86009

Changsha, China
Site CN86010

Shanghai, China
Site CN86011

Shenzhen, China
Site CN86012

Tianjin, China
Site CN86013

Shanghai, China
Site CN86014

Shanghai, China
Site CN86016

Changsha, China
Site CN86017

Zhengzhou, China
Site CN86019

Wuhan, China
Site CN86020

Shenyang, China
Site CN86021

Wuxi, China
Site CN86022

Beijing, China
Site CN86023

Changsha, China
Site CN86024

Changchun, China
Site CN86025

Fuzhou, China
Site CN86026

Wuhan, China
Site CN86027

Shanghai, China
Site CN86028

Hangzhou, China
Site CN86029

Zhengzhou, China
Site CN86032

Suzhou, China
Site CN86035

Beijing, China
Site CN86036

Hangzhou, China
Site CN86038

Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.